Cargando…
Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
Cancers express tryptophan catabolising enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) to produce immunosuppressive tryptophan metabolites that undermine patients’ immune systems, leading to poor disease outcomes. Both enzymes are validated targets for cancer immu...
Autores principales: | Sari, Suat, Tomek, Petr, Leung, Euphemia, Reynisson, Jóhannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930675/ https://www.ncbi.nlm.nih.gov/pubmed/31795096 http://dx.doi.org/10.3390/molecules24234346 |
Ejemplares similares
-
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
Identification and Characterization of a Novel Dual Inhibitor of
Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase
por: Yoshioka, Saeko, et al.
Publicado: (2022) -
A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases
por: Zhou, Qihui, et al.
Publicado: (2021) -
The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011) -
Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)